Cue Biopharma

NASDAQ CUE

Data sourced from

and

Daily

Download Data

Cue Biopharma Share Price on June 03, 2024: USD 1.65

Cue Biopharma Share Price is USD 1.65 on June 03, 2024, a -58.44% change year over year. Share price refers to the current trading price of a single share of a company's stock. It represents the monetary value that investors are willing to pay for ownership in the company. Share prices are determined by the supply and demand dynamics in the stock market and can fluctuate throughout the trading day. Changes in share prices are influenced by various factors, including company performance, industry trends, market conditions, investor sentiment, and economic indicators. Share price is a key indicator used by investors to assess the performance and valuation of a company's stock.

Cue Biopharma 52-week high Share Price is USD 4.69 on July 17, 2023, which is 184.24% above the current Share Price.
Cue Biopharma 52-week low Share Price is USD 1.37 on April 26, 2024, which is -16.97% below the current Share Price.
Cue Biopharma average Share Price for the last 52 weeks is USD 2.58.

NASDAQ: CUE

Cue Biopharma

CEO	Mr. Daniel R. Passeri J.D., M.Sc., MSc.
IPO Date	Jan. 2, 2018
Location	United States
Headquarters	21 Erie Street, Cambridge, MA, United States, 02139
Employees	53
Sector	Healthcare
Industry	Biotechnology

Description

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Key trends